Fig. 4

LPS induced microglial activation via the MAPK pathway, and the expression of neuronal HDAC2 is mediated by microglial activity. a Schematic diagram of the in vitro experiments. b The expression of HDAC2 and acetyl-H3 remained unchanged in the BV2 microglia in the LPS group (n = 4). c The expression of p-ERK and p-CREB in BV2 microglia was increased in the LPS group (n = 4). d The expression of HDAC2 in neurons was increased in the BV2 + LPS group compared with the origin neuron medium group (n = 4). Con represent the origin neuron medium, BV2 represents the BV2 microglia untreated medium group and BV2 + L represents the BV2 treated with LPS group. e Compared with the LPS treatment, the ERK inhibitor U0126 significantly decreased the expression of p-ERK in neurons (n = 3). U represents U0126. f The LPS-induced activation of microglia was significantly reversed by U0126. U represents U0126. g Compared with the LPS treatment, the ERK inhibitor U0126 significantly decreased the expression of HDAC2 in neurons (n = 3). Data are presented as the mean ± S.E.M. ^*P < 0.05; ^**P < 0.01; and ^***P < 0.001